These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

699 related items for PubMed ID: 24998880

  • 21. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.
    Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
    [Abstract] [Full Text] [Related]

  • 22. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM.
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial.
    Sterling R, Lim J, Frith L, Snowise NG, Jacques L, Haumann B.
    Respir Med; 2012 Aug; 106(8):1110-5. PubMed ID: 22520084
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial.
    Woodcock A, Bleecker ER, Lötvall J, O'Byrne PM, Bateman ED, Medley H, Ellsworth A, Jacques L, Busse WW.
    Chest; 2013 Oct; 144(4):1222-1229. PubMed ID: 23846316
    [Abstract] [Full Text] [Related]

  • 25. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
    Sliwka A, Jankowski M, Gross-Sondej I, Storman M, Nowobilski R, Bala MM.
    Cochrane Database Syst Rev; 2018 Aug 24; 8(8):CD012355. PubMed ID: 30141826
    [Abstract] [Full Text] [Related]

  • 26. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial.
    Singh D, Worsley S, Zhu CQ, Hardaker L, Church A.
    BMC Pulm Med; 2015 Aug 19; 15():91. PubMed ID: 26286141
    [Abstract] [Full Text] [Related]

  • 27. Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.
    McKeage K.
    Drugs; 2014 Sep 19; 74(13):1509-22. PubMed ID: 25074268
    [Abstract] [Full Text] [Related]

  • 28. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
    Moretz C, Sharpsten L, Bengtson LG, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2019 Sep 19; 14():1721-1737. PubMed ID: 31534326
    [Abstract] [Full Text] [Related]

  • 29. The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
    Kempsford R, Allen A, Bareille P, Hamilton M, Cheesbrough A.
    Clin Pharmacol Drug Dev; 2015 Jan 19; 4(1):2-11. PubMed ID: 27127998
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk.
    Covelli H, Pek B, Schenkenberger I, Scott-Wilson C, Emmett A, Crim C.
    Int J Chron Obstruct Pulmon Dis; 2016 Jan 19; 11():1-12. PubMed ID: 26730183
    [Abstract] [Full Text] [Related]

  • 31. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C, Kässner F, Banik N, Ntampakas P, Fielder K.
    Respir Med; 2013 Apr 19; 107(4):542-9. PubMed ID: 23337300
    [Abstract] [Full Text] [Related]

  • 32. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
    Bollmeier SG, Prosser TR.
    Ann Pharmacother; 2014 Feb 19; 48(2):250-7. PubMed ID: 24259654
    [Abstract] [Full Text] [Related]

  • 33. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma.
    O'Byrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, Toler WT, Jacques L, Lötvall J.
    Eur Respir J; 2014 Mar 19; 43(3):773-82. PubMed ID: 24136330
    [Abstract] [Full Text] [Related]

  • 34. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial.
    Busse WW, O'Byrne PM, Bleecker ER, Lötvall J, Woodcock A, Andersen L, Hicks W, Crawford J, Jacques L, Apoux L, Bateman ED.
    Thorax; 2013 Jun 19; 68(6):513-20. PubMed ID: 23440247
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P.
    Clin Ther; 2006 Jan 19; 28(1):73-85. PubMed ID: 16490581
    [Abstract] [Full Text] [Related]

  • 36. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G, Walker RR, Brooks J, Mehta R, Crater G.
    Pulm Pharmacol Ther; 2012 Dec 19; 25(6):465-71. PubMed ID: 22955035
    [Abstract] [Full Text] [Related]

  • 37. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.
    Oliver A, VanBuren S, Allen A, Hamilton M, Tombs L, Inamdar A, Kempsford R.
    Clin Ther; 2014 Jun 01; 36(6):928-939.e1. PubMed ID: 24793536
    [Abstract] [Full Text] [Related]

  • 38. Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma.
    Braithwaite I, Williams M, Power S, Pilcher J, Weatherall M, Baines A, Moynihan J, Kempsford R, Beasley R, FF/VI Study Team.
    Respir Med; 2016 Oct 01; 119():115-121. PubMed ID: 27692131
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist.
    Lin J, Tang H, Chen P, Wang H, Kim MK, Crawford J, Jacques L, Stone S.
    Allergy Asthma Proc; 2016 Jul 01; 37(4):302-10. PubMed ID: 27401316
    [Abstract] [Full Text] [Related]

  • 40. Vilanterol and fluticasone furoate for asthma.
    Dwan K, Milan SJ, Bax L, Walters N, Powell C.
    Cochrane Database Syst Rev; 2016 Sep 01; 9(9):CD010758. PubMed ID: 27582089
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.